Literature DB >> 26362577

Prevalence of subcutaneous implantable cardioverter-defibrillator candidacy based on template ECG screening in patients with hypertrophic cardiomyopathy.

Niccolo' Maurizi1, Iacopo Olivotto2, Louise R A Olde Nordkamp3, Katia Baldini3, Carlo Fumagalli4, Tom F Brouwer3, Reinoud E Knops3, Franco Cecchi4.   

Abstract

BACKGROUND: Subcutaneous implantable cardioverter-defibrillator (S-ICD) is a promising option for patients with hypertrophic cardiomyopathy (HCM). Patients with HCM can present markedly abnormal electrocardiograms (ECGs), and there are no data on what percentage of patients with HCM fail the prerequisite S-ICD vector screening.
OBJECTIVE: The purpose of this study was to determine the failure rate of the prerequisite vector screening using 1 or 2 acceptable vectors stratified for risk profile for sudden cardiac death and predictors of failure.
METHODS: ECG recordings from consecutive patients with HCM simulating the S-ICD sensing vectors were analyzed with the S-ICD screening tool. Eligibility was defined by 1 or 2 appropriate vectors. Medical history, ultrasound characteristics, and 12-lead ECG characteristics were analyzed and the individual arrhythmic risk at 5 year was determined to study potential predictors of failure.
RESULTS: One hundred sixty-five (118 men; mean age 51 ± 16 years) patients were analyzed. Twenty-two patients (13%) had a high risk of sudden cardiac death, 33 (20%) had intermediate to high risk, and 110 (67%) had low risk. Twenty-six patients (16%) had no suitable vector, including 8 of 22 high-risk patients (36%). The primary cause of failure was high T-wave voltages in 25% of the vectors analyzed. T-wave inversions in >2 leads on the surface 12-lead ECG (odds ratio 15.6; 95% confidence interval 4.9-50.3; P < .001) and prior myectomy (odds ratio 8.4; 95% confidence interval 2.1-33.1; P = .002) were significantly associated with screening failure in a multivariable model.
CONCLUSION: Currently available preimplant screening algorithms recommended by the manufacturer are associated with a significant failure rate in patients with HCM, particularly in the high-risk subgroup.
Copyright © 2016 Heart Rhythm Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Defibrillator screening; Hypertrophic cardiomyopathy; Inappropriate shocks; Subcutaneous implantable cardioverter-defibrillator; Sudden cardiac death; T-wave oversensing

Mesh:

Year:  2015        PMID: 26362577     DOI: 10.1016/j.hrthm.2015.09.007

Source DB:  PubMed          Journal:  Heart Rhythm        ISSN: 1547-5271            Impact factor:   6.343


  11 in total

1.  Prevalence of subcutaneous implantable cardioverter-defibrillator based on template ECG screening and ineligible surface ECG predicting factors in patients with hypertrophic cardiomyopathy in China.

Authors:  Lanyan Guo; Minxia Zhang; Miaoyang Hu; Bo Wang; Jing Wang; Lei Zuo; Weiping Yang; Bing Liu; Liwen Liu
Journal:  Heart Vessels       Date:  2018-11-21       Impact factor: 2.037

2.  Subcutaneous implantable cardioverter defibrillator eligibility according to a novel automated screening tool and agreement with the standard manual electrocardiographic morphology tool.

Authors:  Pietro Francia; Matteo Ziacchi; Paolo De Filippo; Stefano Viani; Antonio D'Onofrio; Vincenzo Russo; Carmen Adduci; Mauro Biffi; Paola Ferrari; Valter Bianchi; Ernesto Ammendola; Francesca Palano; Jessica Frisoni; Sergio Valsecchi; Mariolina Lovecchio; Maria Grazia Bongiorni
Journal:  J Interv Card Electrophysiol       Date:  2018-03-03       Impact factor: 1.900

Review 3.  [Management of inappropriate shocks/T-wave-oversensing in S-ICD®-patients].

Authors:  Robert Larbig; Markus Bettin; Lukas J Motloch; Alicia Fischer; Niklas Bode; Gerrit Frommeyer; Florian Reinke; Andreas Loeher; Lars Eckardt; Julia Köbe
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2018-02-12

4.  Analysis of Screening Electrocardiogram for the Subcutaneous Defibrillator in Adults with Congenital Heart Disease.

Authors:  Vincent C Thomas; Mark Peterson; Martin McDaniel; Humberto Restrepo; Abraham Rothman; Amit Jain
Journal:  Pediatr Cardiol       Date:  2017-05-22       Impact factor: 1.655

5.  Deep learning-based insights on T:R ratio behaviour during prolonged screening for S-ICD eligibility.

Authors:  Mohamed ElRefai; Mohamed Abouelasaad; Benedict M Wiles; Anthony J Dunn; Stefano Coniglio; Alain B Zemkoho; Paul R Roberts
Journal:  J Interv Card Electrophysiol       Date:  2022-05-13       Impact factor: 1.900

6.  Transvenous or subcutaneous implantable cardioverter defibrillator: a review to aid decision-making.

Authors:  Milena Leo; Alexander J Sharp; Andre Briosa E Gala; Michael T B Pope; Timothy R Betts
Journal:  J Interv Card Electrophysiol       Date:  2022-07-14       Impact factor: 1.759

7.  The utility of routine clinical 12-lead ECG in assessing eligibility for subcutaneous implantable cardioverter defibrillator.

Authors:  Jason A Thomas; Erick Andres Perez-Alday; Christopher Hamilton; Muammar M Kabir; Eugene A Park; Larisa G Tereshchenko
Journal:  Comput Biol Med       Date:  2018-05-08       Impact factor: 4.589

8.  Appropriate and inappropriate shocks in hypertrophic cardiomyopathy patients with subcutaneous implantable cardioverter-defibrillators: An international multicenter study.

Authors:  Babak Nazer; Zack Dale; Gianmarco Carrassa; Nosheen Reza; Tuna Ustunkaya; Nikolaos Papoutsidakis; Andrew Gray; Stacey J Howell; Miriam R Elman; Paolo Pieragnoli; Giuseppe Ricciardi; Daniel Jacoby; David S Frankel; Anjali Owens; Iacopo Olivotto; Stephen B Heitner
Journal:  Heart Rhythm       Date:  2020-02-18       Impact factor: 6.343

9.  Inappropriate subcutaneous implantable cardioverter-defibrillator therapy due to R-wave amplitude variation: Another challenge in device management.

Authors:  Syeda A Batul; Felix Yang; Karan Wats; Suvash Shrestha; Yisachar J Greenberg
Journal:  HeartRhythm Case Rep       Date:  2016-09-28

Review 10.  Update on hypertrophic cardiomyopathy and a guide to the guidelines.

Authors:  Srijita Sen-Chowdhry; Daniel Jacoby; James C Moon; William J McKenna
Journal:  Nat Rev Cardiol       Date:  2016-09-29       Impact factor: 32.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.